SINGAPORE, May 13, 2024 /PRNewswire/ -- Maxeon Solar Technologies, Ltd. (NASDAQ: MAXN) (the "Company"), a global leader in solar innovation and channels, today announced it will postpone the release of its Fourth Quarter, Fiscal Year 2023 and First Quarter 2024 Financial Results, previously scheduled for May 15, 2024 U.S. ET / May 16, Singapore Time, to May 23, 2024. The additional time is necessary to complete the Company's preparation of its annual and quarterly reports and to provide the market with a comprehensive business update.

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), announced today that it closed upon the initial tranche of a private placement (the “Private Offering”) pursuant to the Securities Purchase Agreement (the “Agreement”) with an institutional investor (the “Investor”).

ROCHESTER, N.Y., May 14, 2024 /PRNewswire/ -- Vuzix® Corporation (NASDAQ: VUZI), ("Vuzix" or, the "Company"), a leading supplier of smart glasses and Augmented Reality (AR) technology and products, is pleased to announce that the Company has signed a multi-phase development contract with Garmin for next generation nano-imprinted waveguide-based display system.

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow’s rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow’s commitment to enhancing its leadership structure to support the Company’s continued growth. John Saharek, Harrow’s Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow’s commercial business, focusing on the day-to-day management of Harrow’s market‑leading compounded division.